A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study terminated because the clinical development programme for Ceralasertib has been discontinued.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumours
Interventions
- Drug: Ceralasertib — also filed as AZD6738
- Drug: Drug X
- Drug: Drug Y
- Drug: Drug Z
Primary outcomes
what the primary-completion date above is the date OFArea under plasma concentration-time curve from time 0 to infinity (AUCinf)
measured From Day 5 to Day 30
Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)
measured From Day 5 to Day 30
Maximum observed concentration (Cmax)
measured From Day 5 to Day 30
Plasma terminal elimination half-life (plasma t1/2λz)
measured From Day 5 to Day 30
Terminal elimination rate constante (λz)
measured From Day 5 to Day 30
Time to Reach Maximum Concentration Following Drug Administration (tmax)
measured From Day 5 to Day 30
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed